<?xml version="1.0" encoding="UTF-8"?>
<search_results count="105">
  <query>Telaprevir</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT00561015</nct_id>
    <title>A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013513</other_id>
      <other_id>VX-950-TiDP24-C209</other_id>
    </other_ids>
    <first_received>November 19, 2007</first_received>
    <start_date>December 2007</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>June 7, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>March 8, 2013</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Day 15</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) for Telaprevir on Day 1</outcome_measure>
      <outcome_measure>Time to Reach Maximum Plasma Concentration (Tmax) for Telaprevir on Day 1</outcome_measure>
      <outcome_measure>Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 1</outcome_measure>
      <outcome_measure>Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Week 24 and Week 26</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) for Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) for Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Virological Response (HCV RNA Level &lt; 10 IU/ml)</outcome_measure>
      <outcome_measure>Median Time to Virological Response (HCV RNA Level &lt; 10 IU/ml)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants Who Demonstrated Virological Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Virological Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00561015</url>
  </study>
  <study rank="2">
    <nct_id>NCT01600976</nct_id>
    <title>A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatic Impairment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100872</other_id>
      <other_id>VX-950HPC1001</other_id>
      <other_id>2012-001627-13</other_id>
    </other_ids>
    <first_received>May 15, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>November 8, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Comparing the maximum plasma analyte concentration (Cmax) of telaprevir in patients of Group 2 and Group 1</outcome_measure>
      <outcome_measure>Comparing the area under the plasma concentration-time curve (AUC8h) of telaprevir in patients of Group 2 and Group 1</outcome_measure>
      <outcome_measure>Comparing the actual sampling time to reach the maximum plasma analyte concentration (tmax) of telaprevir in patients of Group 2 and Group 1</outcome_measure>
      <outcome_measure>Number of adverse events in Group 1 patients as a measure of safety</outcome_measure>
      <outcome_measure>Comparing unbound fractions of telaprevir in patients of Group 1 and Group 2</outcome_measure>
      <outcome_measure>Comparing any relationship between the measures of hepatic function and selected pharmacokinetic parameters of telaprevir in patients of Group 1 and Group 2</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01600976</url>
  </study>
  <study rank="3">
    <nct_id>NCT01657552</nct_id>
    <title>Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thrombocytopaenia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eltrombopag</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>116010</other_id>
    </other_ids>
    <first_received>August 2, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>May 16, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Composite pharmacokinetic (PK) parameters of eltrombopag following administration of boceprevir for 10 days with a single dose of eltrombopag</outcome_measure>
      <outcome_measure>Composite PK parameters of boceprevir following administration of boceprevir for 10 days with a single dose of eltrombopag</outcome_measure>
      <outcome_measure>Composite PK parameters of eltrombopag following administration of telaprevir for 10 days with a single dose of eltrombopag</outcome_measure>
      <outcome_measure>Composite PK parameters of telaprevir following administration of telaprevir for 10 days with a single dose of eltrombopag</outcome_measure>
      <outcome_measure>Composite PK parameters of eltrombopag following administration of boceprevir for 10 days with a single dose of eltrombopag</outcome_measure>
      <outcome_measure>Safety and tolerability as assessed by the collection of adverse events</outcome_measure>
      <outcome_measure>Safety and tolerability as assessed by change from baseline in clinical laboratory tests</outcome_measure>
      <outcome_measure>Safety and tolerability as assessed by change from baseline in vital sign</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01657552</url>
  </study>
  <study rank="4">
    <nct_id>NCT00580801</nct_id>
    <title>An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated-interferon-alfa-2a</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013714</other_id>
      <other_id>VX-950-TiDP24-C210</other_id>
    </other_ids>
    <first_received>December 20, 2007</first_received>
    <start_date>January 2008</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>August 27, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>March 7, 2013</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Response (Undetectable HCV RNA)</outcome_measure>
      <outcome_measure>Median Time to First Viral Response (Undetectable HCV RNA)</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough (Detectable HCV RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Area Under the Serum Concentration-Time Curve (AUC)</outcome_measure>
      <outcome_measure>Maximum Serum Concentration (Cmax) of Telaprevir</outcome_measure>
      <outcome_measure>Pre-Dose Serum Concentration (C[0h]) of Telaprevir</outcome_measure>
      <outcome_measure>Minimum Serum Concentration (Cmin) of Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Time to Reach the Maximum Serum Concentration (Tmax) of Telaprevir</outcome_measure>
      <outcome_measure>Average Steady-State Serum Concentration (Css,av) of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00580801</url>
  </study>
  <study rank="5">
    <nct_id>NCT00933283</nct_id>
    <title>A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Participants</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Methadone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015931</other_id>
      <other_id>VX-950-TiDP24-C135</other_id>
    </other_ids>
    <first_received>July 2, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>November 30, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum plasma concentration (Cmax) of telaprevir</outcome_measure>
      <outcome_measure>Minimum plasma concentration (Cmin) of telaprevir</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve (AUC) of telaprevir</outcome_measure>
      <outcome_measure>Cmax of R-methadone</outcome_measure>
      <outcome_measure>Cmin of R-methadone</outcome_measure>
      <outcome_measure>AUC of R-methadone</outcome_measure>
      <outcome_measure>Cmax of S-methadone</outcome_measure>
      <outcome_measure>Cmin of S-methadone</outcome_measure>
      <outcome_measure>AUC of S-methadone</outcome_measure>
      <outcome_measure>Short Opiate Withdrawal Scale [SOWS]</outcome_measure>
      <outcome_measure>Desires for Drugs Questionnaire [DDQ]</outcome_measure>
      <outcome_measure>Pupillometry</outcome_measure>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00933283</url>
  </study>
  <study rank="6">
    <nct_id>NCT01336829</nct_id>
    <title>TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ETR/telaprevir</intervention>
      <intervention type="Drug">TMC278/telaprevir</intervention>
      <intervention type="Drug">telaprevir/ETR</intervention>
      <intervention type="Drug">telaprevir/TMC278</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017989</other_id>
      <other_id>TMC125IFD1001</other_id>
    </other_ids>
    <first_received>April 7, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>August 28, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Bloodlevels of telaprevir following co-administration with ETR</outcome_measure>
      <outcome_measure>Bloodlevels of telaprevir following co-administration with TMC278</outcome_measure>
      <outcome_measure>Bloodlevels of ETR following co-administration with telaprevir</outcome_measure>
      <outcome_measure>Bloodlevels of TMC278 following co-administration with telaprevir</outcome_measure>
      <outcome_measure>Number of participants with adverse events and the severity of adverse events</outcome_measure>
      <outcome_measure>Bloodlevels of ETR in function of variations of 2 genes (CYP2C9 and CYP2C19)</outcome_measure>
      <outcome_measure>Observed values and changes from baseline for abnormal values of laboratory results.</outcome_measure>
      <outcome_measure>Observed values and changes from baseline for electrocardiograms (interpretation of electrical activity of the heart)</outcome_measure>
      <outcome_measure>Evaluation of pulse and blood pressure values, based on changes from baseline and the percentage of participants with values beyond clinically important limits</outcome_measure>
      <outcome_measure>Physical examination findings and changes from baseline.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01336829</url>
  </study>
  <study rank="7">
    <nct_id>NCT01332955</nct_id>
    <title>Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Biological">pegIFN alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Janssen-Cilag Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2010-023287-41</other_id>
      <other_id>ANRS HC26 TelapreVIH</other_id>
    </other_ids>
    <first_received>March 28, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>January 22, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TelapreVIH</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Estimation of SVR following a 12 wks treatment by telaprevir combined with a 48 or 72 wks peginterferon-ribavirin treatment, based upon the rapid virological response, and comparison to 20% (which would correspond to a significant therapeutic benefit)</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Estimation of the Sustained Virological Response defined as undetectable HCV-RNA at Week 12 after the end of HCV treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01332955</url>
  </study>
  <study rank="8">
    <nct_id>NCT01646489</nct_id>
    <title>Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Miravirsen sodium</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Santaris Pharma A/S</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SPC3649-206</other_id>
    </other_ids>
    <first_received>July 4, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>November 9, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The effect of miravirsen on telaprevir pharmacokinetics as determined by AUC0-24h, Cmax and tmax.</outcome_measure>
      <outcome_measure>Safety and tolerability of co-administered miravirsen and telaprevir.</outcome_measure>
      <outcome_measure>The effect of telaprevir on miravirsen pharmacokinetics as determined by AUC0-24h, Cmax and tmax.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01646489</url>
  </study>
  <study rank="9">
    <nct_id>NCT01459913</nct_id>
    <title>Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>239</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-114</other_id>
    </other_ids>
    <first_received>October 24, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>May 14, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>January 26, 2015</firstreceived_results_date>
    <acronym>CONCISE</acronym>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Subjects With On-Treatment Virologic Failure</outcome_measure>
      <outcome_measure>Number of Subjects With Rapid Viral Response (RVR)</outcome_measure>
      <outcome_measure>Number of Subjects With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01459913</url>
  </study>
  <study rank="10">
    <nct_id>NCT00775125</nct_id>
    <title>VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Telaprevir</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir; Darunavir; Ritonavir; Fosamprenavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015208</other_id>
    </other_ids>
    <first_received>October 16, 2008</first_received>
    <start_date>June 2008</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>December 16, 2010</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effect of steady-state DRV/rtv 600/100 mg b.i.d. and steady-state of fAPV/rtv 700/100 mg on the steady-state PK of telaprevir 750 mg q8h and 1125 mg q12h and vice versa. Steady-state PK on telaprevir 750 mg q8h and 1125 mg q12h alone.</outcome_measure>
      <outcome_measure>The secondary objective is to determine the short-term safety and tolerability of coadministration of telaprevir and DRV/rtv, and telaprevir and fAPV/rtv.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00775125</url>
  </study>
  <study rank="11">
    <nct_id>NCT01841502</nct_id>
    <title>Interaction Between Paroxetine and Telaprevir</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Paroxetine</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
      <collaborator>Janssen, LP</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AKF UMCN 12.02</other_id>
    </other_ids>
    <first_received>April 2, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>October 27, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ROLEX</acronym>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>paroxetine area under the curve (AUC)</outcome_measure>
      <outcome_measure>paroxetine Cmax and C24</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>short term HCV RNA response</outcome_measure>
      <outcome_measure>telaprevir area under the curve (AUC)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01841502</url>
  </study>
  <study rank="12">
    <nct_id>NCT00528528</nct_id>
    <title>An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2b</intervention>
      <intervention type="Drug">Ribavirin (RBV) tablet</intervention>
      <intervention type="Drug">Ribavirin (RBV) capsule</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>166</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013516</other_id>
      <other_id>VX-950-TIDP24-C208</other_id>
      <other_id>2007-001044-44</other_id>
    </other_ids>
    <first_received>September 10, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>August 2009</completion_date>
    <last_updated>June 13, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>March 18, 2013</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Virologic Response at Week 12</outcome_measure>
      <outcome_measure>Time to First Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at Week 12</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After End of Treatment (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00528528</url>
  </study>
  <study rank="13">
    <nct_id>NCT01635829</nct_id>
    <title>A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Participants</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Phenytoin</intervention>
      <intervention type="Drug">Carbamazepine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100830</other_id>
      <other_id>VX-950HPC1002</other_id>
      <other_id>2012-001411-23</other_id>
    </other_ids>
    <first_received>July 4, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>October 23, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Observed maximum plasma concentration (Cmax) of telaprevir.</outcome_measure>
      <outcome_measure>Area under the plasma concentration time curve from time of administration up to 8 hours post dose (AUC8h) of telaprevir.</outcome_measure>
      <outcome_measure>Observed minimum plasma concentration (Cmin) of telaprevir.</outcome_measure>
      <outcome_measure>Observed maximum plasma concentration (Cmax) of carbamazepine.</outcome_measure>
      <outcome_measure>Area under the plasma concentration time curve from time of administration up to 12 hours post dose (AUC12) of carbamazepine.</outcome_measure>
      <outcome_measure>Observed minimum plasma concentration (Cmin) of carbamazepine.</outcome_measure>
      <outcome_measure>Observed maximum plasma concentration (Cmax) of phenytoin.</outcome_measure>
      <outcome_measure>Area under the plasma concentration time curve from time of administration up to 12 hours post dose (AUC12) of phenytoin.</outcome_measure>
      <outcome_measure>Observed minimum plasma concentration (Cmin) of phenytoin.</outcome_measure>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Number of participants with abnormal values of laboratory results</outcome_measure>
      <outcome_measure>Number of participants with abnormal electrocardiogram values</outcome_measure>
      <outcome_measure>Number of participants with abnormal pulse and blood pressure values</outcome_measure>
      <outcome_measure>Number of patients with abnormal physical examination findings</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01635829</url>
  </study>
  <study rank="14">
    <nct_id>NCT01821963</nct_id>
    <title>Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2012-0977</other_id>
    </other_ids>
    <first_received>March 27, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>February 23, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>February 23, 2015</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Undetectable Viral Load 12 Weeks Post-transplant</outcome_measure>
      <outcome_measure>Sustained Virological Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01821963</url>
  </study>
  <study rank="15">
    <nct_id>NCT00703118</nct_id>
    <title>A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>663</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR014842</other_id>
      <other_id>VX-950-TIDP24-C216</other_id>
    </other_ids>
    <first_received>June 19, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>December 5, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>July 18, 2011</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After the Last Planned Dose of Study Medication - SVR24 Planned</outcome_measure>
      <outcome_measure>Number of Participants Acheiving Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Number of Participants Acheiving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 48 (End of Treatment)</outcome_measure>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Medication - SVR12 Planned</outcome_measure>
      <outcome_measure>Number of Participants Who Meet the Telaprevir Stopping Rule at Week 4, Week 6, or Week 8</outcome_measure>
      <outcome_measure>Number of Participants Who Have Viral Relapse During Entire Follow-up Period (up to Week 72)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4</outcome_measure>
      <outcome_measure>Number of Participants Acheiving Extended Rapid Virologic Response at Week 4 and Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00703118</url>
  </study>
  <study rank="16">
    <nct_id>NCT00420784</nct_id>
    <title>A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Matching Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>465</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX06-950-106</other_id>
    </other_ids>
    <first_received>January 8, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>July 9, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00420784</url>
  </study>
  <study rank="17">
    <nct_id>NCT00627926</nct_id>
    <title>A Phase 3 Study of Telaprevir in Combination With Pegasys and Copegus in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1095</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX07-950-108</other_id>
    </other_ids>
    <first_received>February 22, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>July 16, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA at Week 72</outcome_measure>
      <outcome_measure>Number of Subjects Achieving Rapid Viral Response (RVR), Demonstrated by Achieving Undetectable HCV RNA 4 Weeks After Starting Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects Achieving Extended Rapid Viral Response (eRVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA 12 Weeks After Last Planned Dose of Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA 24 Weeks After Last Actual Dose of Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse Planned and Viral Relapse Actual</outcome_measure>
      <outcome_measure>Biochemical Response: Number of Subjects With Grade 3 and 4 Shifts From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels</outcome_measure>
      <outcome_measure>Noninvasive Markers of Fibrosis: Number of Subjects With Improvement in FibroTest Analysis</outcome_measure>
      <outcome_measure>Fatigue Severity Scale (FSS) Total Score</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00627926</url>
  </study>
  <study rank="18">
    <nct_id>NCT02113631</nct_id>
    <title>Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C,</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peg-IFN</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Louis Stokes VA Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB #: 11064-H40</other_id>
    </other_ids>
    <first_received>March 30, 2014</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>April 10, 2014</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/Adverse Event Outcome Measure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02113631</url>
  </study>
  <study rank="19">
    <nct_id>NCT01054573</nct_id>
    <title>VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">pegylated interferon (Peg-IFN) alfa-2a</intervention>
      <intervention type="Drug">ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016678</other_id>
      <other_id>VX-TiDP24-C219</other_id>
      <other_id>2009-012613-21</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>April 2010</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>May 6, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>March 8, 2013</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response (SVR) 24 Weeks After the Last Dose of Study Drug (SVR24 Actual)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected at Different Time Points</outcome_measure>
      <outcome_measure>Percentage of Participants Who Met a Virologic Stopping Rule That Required Them to Permanently Discontinue Telaprevir and Continue Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) at Week 4 or Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants Who Met a Virologic Stopping Rule That Required Them to Permanently Discontinue All Study Drugs at Week 12, 24, or 36</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants Who Relapsed During Follow-Up</outcome_measure>
      <outcome_measure>Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values Over Time</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01054573</url>
  </study>
  <study rank="20">
    <nct_id>NCT01253551</nct_id>
    <title>VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Treatment sequence AB</intervention>
      <intervention type="Drug">Treatment sequence BA</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017608</other_id>
      <other_id>VX-950HEP1001</other_id>
    </other_ids>
    <first_received>December 2, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>October 13, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Blood levels of telaprevir and raltegravir when given alone versus when given together</outcome_measure>
      <outcome_measure>Percentage of participants with a given adverse event as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Clinical laboratory abnormalities as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Vital signs observed values and changes from baseline as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Physical examination findings and changes from baseline as a measure of safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01253551</url>
  </study>
  <study rank="21">
    <nct_id>NCT01511432</nct_id>
    <title>A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir formulation A</intervention>
      <intervention type="Drug">telaprevir Formulation B</intervention>
      <intervention type="Drug">telaprevir Formulation C</intervention>
      <intervention type="Drug">telaprevir Formulation D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-025</other_id>
    </other_ids>
    <first_received>January 9, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>July 3, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>PK parameters: Maximum plasma concentration (Cmax), area under the concentration versus time curve (AUC) from time 0 to infinity (AUC0-)</outcome_measure>
      <outcome_measure> PK parameters: Maximum plasma concentration (Cmax), area under the concentration versus time curve AUC from time 0 to last time point (AUC0-tlast)</outcome_measure>
      <outcome_measure>The safety and tolerability of 3 oral formulations of telaprevir as assessed by adverse events, serious adverse events and results of clinical laboratory tests (serum chemistry, hematology, and urinalysis), vital signs, and 12-lead electrocardiograms</outcome_measure>
      <outcome_measure>Time to reach Cmax after dosing (tmax) and terminal half-life (t1/2) of telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01511432</url>
  </study>
  <study rank="22">
    <nct_id>NCT01467492</nct_id>
    <title>Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-116</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>July 13, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>June 1, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 12 Weeks After Last Actual Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After Last Actual Dose of Study Drug (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With On Treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01467492</url>
  </study>
  <study rank="23">
    <nct_id>NCT01498068</nct_id>
    <title>Open-Label, Bridging Study of Telaprevir in Treatment-Nave and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Genotype 1 Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated-interferon-alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100676</other_id>
      <other_id>VX-950HPC3007</other_id>
    </other_ids>
    <first_received>December 6, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>January 29, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>September 11, 2013</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Median Change in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Number of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Less Than 25 IU/mL, (Target Not Detected) at Weeks 8, 12, 24, 32, 40 and 48</outcome_measure>
      <outcome_measure>Number of Participants With Virologic Failure</outcome_measure>
      <outcome_measure>Number of Participants in Each Specific Category of Treatment Outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01498068</url>
  </study>
  <study rank="24">
    <nct_id>NCT01597895</nct_id>
    <title>Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Maraviroc</intervention>
      <intervention type="Drug">Maraviroc + Boceprevir</intervention>
      <intervention type="Drug">Maraviroc + Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ViiV Healthcare</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A4001108</other_id>
    </other_ids>
    <first_received>May 10, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>September 18, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maraviroc plasma pharmacokinetic parameters: AUC12, Cmax, and C12h on Period 1, Day 5 and Periods 2 and 3, Day 10</outcome_measure>
      <outcome_measure>Maraviroc plasma pharmacokinetic parameters: Tmax on Period 1, Day 5 and Periods 2 and 3, Day 10</outcome_measure>
      <outcome_measure>Boceprevir plasma pharmacokinetic parameters: AUC8, Cmax, C8h, and Tmax on Period 2, Day 10</outcome_measure>
      <outcome_measure>Telaprevir plasma pharmacokinetic parameters: AUC8, Cmax, C8h, and Tmax on Period 3, Day 10</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01597895</url>
  </study>
  <study rank="25">
    <nct_id>NCT01500616</nct_id>
    <title>Telaprevir Open-Label Study in Co-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>122</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018787</other_id>
      <other_id>VX-950HPC3005</other_id>
      <other_id>2011-003593-85</other_id>
    </other_ids>
    <first_received>December 22, 2011</first_received>
    <start_date>June 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>August 21, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment-emergent Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Ireland</country>
      <country>Luxembourg</country>
      <country>Portugal</country>
      <country>Russian Federation</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01500616</url>
  </study>
  <study rank="26">
    <nct_id>NCT01241760</nct_id>
    <title>VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-nave Participants With Genotype 1 Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Genotype 1 Chronic Hepatitis C</condition>
      <condition>Treatment Naive</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>744</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013711</other_id>
      <other_id>OPTIMIZE-HCV</other_id>
      <other_id>VX-950-C211</other_id>
      <other_id>2010-021628-84</other_id>
    </other_ids>
    <first_received>October 28, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>May 14, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>September 23, 2013</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs</outcome_measure>
      <outcome_measure>Percentage of Participants Who Relapsed During Follow-up Period</outcome_measure>
      <outcome_measure>Percentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01241760</url>
  </study>
  <study rank="27">
    <nct_id>NCT01890772</nct_id>
    <title>Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Dietary Supplement">Vitamin D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Timothy Morgan, MD</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
      <collaborator>Southern California Institute for Research and Education</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1217</other_id>
    </other_ids>
    <first_received>May 31, 2013</first_received>
    <start_date>August 2013</start_date>
    <last_updated>May 13, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA</outcome_measure>
      <outcome_measure>adverse event profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01890772</url>
  </study>
  <study rank="28">
    <nct_id>NCT00372385</nct_id>
    <title>Phase 2 Study of VX-950, Pegasys With and Without Copegus in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>334</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX05-950-104EU</other_id>
    </other_ids>
    <first_received>September 1, 2006</first_received>
    <start_date>August 2006</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>June 25, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Week 12 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00372385</url>
  </study>
  <study rank="29">
    <nct_id>NCT00336479</nct_id>
    <title>Phase 2 Study of VX-950, Pegasys, and Copegus in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>263</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX05-950-104</other_id>
    </other_ids>
    <first_received>June 9, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>June 25, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Week 12 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00336479</url>
  </study>
  <study rank="30">
    <nct_id>NCT01513941</nct_id>
    <title>An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated-Interferon-alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>163</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100778</other_id>
      <other_id>VX-950HPC3008</other_id>
      <other_id>2011-004928-35</other_id>
    </other_ids>
    <first_received>January 16, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>May 22, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>INSIGHT</acronym>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients achieving undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels</outcome_measure>
      <outcome_measure>Change from baseline in log HCV RNA values</outcome_measure>
      <outcome_measure>Proportiond of patients achieving undetectable HCV RNA levels</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA levels at Week 4</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA levels at Week 12</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA levels at Week 4 and Week 12 (eRVR)</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA at the actual end of treatment</outcome_measure>
      <outcome_measure>Proportion of patients achieving less than 25 IU/mL</outcome_measure>
      <outcome_measure>Proportion of patients with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Proportion of patients with relapse achieving detectable HCV RNA levels after previously undetectable HCV RNA levels</outcome_measure>
      <outcome_measure>Proportion of patients with relapse achieving detectable HCV RNA levels after previous HCV RNA levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01513941</url>
  </study>
  <study rank="31">
    <nct_id>NCT01571583</nct_id>
    <title>An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus (HCV) Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018721</other_id>
      <other_id>VX-950HPC3006</other_id>
      <other_id>2011-004724-35</other_id>
    </other_ids>
    <first_received>December 16, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 14, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>REPLACE</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients achieving sustained virologic response (SVR) 12 planned</outcome_measure>
      <outcome_measure>Number of patients achieving SVR12 planned(c)</outcome_measure>
      <outcome_measure>Number of patients achieving SVR24 planned</outcome_measure>
      <outcome_measure>Number of patients achieving SVR24 planned(c)</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at Week 4 of treatment</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at Week 12 of treatment</outcome_measure>
      <outcome_measure>Number of patients having undetectable HCV RNA levels at Week 4 and Week 12 of treatment</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at the actual end of treatment</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at the planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients having less than 25 IU/mL at the planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Number of patients with relapse after undetectable HCV RNA at actual end of treatment</outcome_measure>
      <outcome_measure>Number of patients with relapse after undetectable HCV RNA at planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients with relapse after previous HCV RNA less than 25 IU/mL at planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients with viral breakthrough</outcome_measure>
      <outcome_measure>Change from baseline in log HCV RNA values</outcome_measure>
      <outcome_measure>Number of patients who have changes in liver graft biopsy histology</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01571583</url>
  </study>
  <study rank="32">
    <nct_id>NCT01038167</nct_id>
    <title>A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">cyclosporine</intervention>
      <intervention type="Drug">cyclosporine</intervention>
      <intervention type="Drug">tacrolimus</intervention>
      <intervention type="Drug">tacrolimus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX09-950-021</other_id>
    </other_ids>
    <first_received>December 18, 2009</first_received>
    <start_date>January 2010</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>April 6, 2010</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A only: Pharmacokinetic parameters of cyclosporine (Cmax, AUC0-tlast, AUC0-inf, tmax, t1/2)</outcome_measure>
      <outcome_measure>Part A and Part B: Pharmacokinetic parameters of telaprevir (Cmax, AUC0-8h, Cmin, tmax)</outcome_measure>
      <outcome_measure>Part B only: Pharmacokinetic parameters of tacrolimus (Cmax, AUC0-tlast, AUC0-inf, tmax, t1/2)</outcome_measure>
      <outcome_measure>Part A and Part B: Safety and tolerability as measured by adverse events, clinical laboratory assessments, electrocardiograms, vital signs, physical examinations</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01038167</url>
  </study>
  <study rank="33">
    <nct_id>NCT00903773</nct_id>
    <title>VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Kidney Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016123</other_id>
    </other_ids>
    <first_received>May 14, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>December 16, 2010</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective of this study is to investigate the effect of severe renal impairment on the single-dose pharmacokinetics of total telaprevir. Total telaprevir is the sum of telaprevir bound to plasma proteins and unbound (free) telaprevir.</outcome_measure>
      <outcome_measure>The effect of severe renal impairment on total and unbound plasma concentrations of the sum of TVR and VRT-127394 will be investigated.</outcome_measure>
      <outcome_measure>Safety and tolerability of a single dose of telaprevir will be determined.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00903773</url>
  </study>
  <study rank="34">
    <nct_id>NCT01467505</nct_id>
    <title>An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Immunosuppressant Regimen</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-117</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>February 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>June 1, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>May 2, 2015</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Viral Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-Treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Pharmacokinetics of Telaprevir, Peg-IFN, RBV , and Selected Immunosuppressant Medications (Tacrolimus and Cyclosporine)</outcome_measure>
      <outcome_measure>Percentage of Participants Requiring Dose Titration of Immunosuppressant Medications</outcome_measure>
      <outcome_measure>Percentage of Participants With Biopsy Confirmed and Treated Rejection</outcome_measure>
      <outcome_measure>Percentage of Participants With Histological Evidence of Stabilization or Improvement in Inflammation Grade or Fibrosis Stage</outcome_measure>
      <outcome_measure>Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01467505</url>
  </study>
  <study rank="35">
    <nct_id>NCT01994486</nct_id>
    <title>Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir and Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>20132125</other_id>
    </other_ids>
    <first_received>November 12, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>February 20, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>February 20, 2015</firstreceived_results_date>
    <acronym>STEADFAST</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Frequency of Adverse Events Leading to Discontinuation of Both Telaprevir and Sofosbuvir Among Subjects Treated With Telaprevir and Sofosbuvir</outcome_measure>
      <outcome_measure>Safety of Telaprevir and Sofosbuvir When Dosed in Combination for 12 Weeks</outcome_measure>
      <outcome_measure>Characterize Steady State of Sofosbuvir Active SOF Metabolite, GS-331007</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Achieve Undetectable Hepatitis C Virus RNA at 12 Weeks After Completing Study Drug Regimen</outcome_measure>
      <outcome_measure>Proportion of Subjects With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01994486</url>
  </study>
  <study rank="36">
    <nct_id>NCT00916474</nct_id>
    <title>Virology Follow up Study in Subjects Previously Treated With Telaprevir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>408</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX08-950-112</other_id>
    </other_ids>
    <first_received>June 4, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>February 26, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who maintain undetectable HCV RNA over time after achieving an SVR following telaprevir-based treatment</outcome_measure>
      <outcome_measure>Change in HCV variants with decreased sensitivity to telaprevir over time in subjects failing to achieve an SVR following telaprevir-based treatment</outcome_measure>
      <outcome_measure>Change in HCV variants with decreased sensitivity to telaprevir over time in subjects with late relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00916474</url>
  </study>
  <study rank="37">
    <nct_id>NCT01467479</nct_id>
    <title>A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Highly Active Antiretroviral Therapy (HAART)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>185</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-115</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>March 3, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>March 3, 2015</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR 24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Viral Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable HCV RNA at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin), and Average Plasma Concentration (Cavg)</outcome_measure>
      <outcome_measure>Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01467479</url>
  </study>
  <study rank="38">
    <nct_id>NCT00892697</nct_id>
    <title>Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>0810010040</other_id>
    </other_ids>
    <first_received>April 30, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 9, 2015</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 18, 2014</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Intrahepatic and Plasma HCV Viral Kinetics</outcome_measure>
      <outcome_measure>Intrahepatic and Peripheral Pharmacokinetic Assessment of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00892697</url>
  </study>
  <study rank="39">
    <nct_id>NCT01516918</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-222</intervention>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon-alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-222-106</other_id>
    </other_ids>
    <first_received>January 13, 2012</first_received>
    <start_date>February 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>October 9, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of subjects who have a sustained virologic response at 12 weeks after the last planned dose of treatment (SVR12)</outcome_measure>
      <outcome_measure>The safety and tolerability as assessed by adverse events, vital signs, 12-lead electrocardiograms and laboratory assessments.</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR 24 weeks after the last planned dose of the study drug (SVR24)</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve undetectable HCV RNA at Weeks 2, 4, 8, and 12 after the first dose of study drug, and at the end of planned study drug treatment</outcome_measure>
      <outcome_measure>The proportion of subjects who have on-treatment virologic failure defined as subjects who either meet a futility rule or who complete the assigned treatment duration and have HCV RNA at the end of study drug treatment</outcome_measure>
      <outcome_measure>The association of the IL-28B genotype with SVR12</outcome_measure>
      <outcome_measure>The amino acid sequence of the nonstructural (NS)3 and NS5B proteins in subjects who have treatment failure</outcome_measure>
      <outcome_measure>VX-222, telaprevir, and RBV plasma concentrations and Peg-IFN serum concentrations</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
      <country>Poland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01516918</url>
  </study>
  <study rank="40">
    <nct_id>NCT01508286</nct_id>
    <title>Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects</title>
    <recruitment open="N">No longer available</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir + peginterferon alfa + ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa + ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <study_designs/>
    <other_ids>
      <other_id>CR017857</other_id>
      <other_id>VX-950HEP3002</other_id>
      <other_id>2010-023669-23</other_id>
    </other_ids>
    <first_received>January 9, 2012</first_received>
    <last_updated>July 22, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Czech Republic</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Hungary</country>
      <country>Luxembourg</country>
      <country>New Zealand</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Serbia</country>
      <country>Spain</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01508286</url>
  </study>
  <study rank="41">
    <nct_id>NCT00983853</nct_id>
    <title>Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir or matching placebo</intervention>
      <intervention type="Drug">telaprevir or matching placebo</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin (fixed dose)</intervention>
      <intervention type="Drug">ribavirin (weight-based dose)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX08-950-110</other_id>
    </other_ids>
    <first_received>September 22, 2009</first_received>
    <start_date>October 2009</start_date>
    <last_updated>August 2, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>August 2, 2013</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Subjects Achieving Undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Proportion of Subjects Achieving Undetectable HCV RNA at Week 4 and Week 12</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have Undetectable HCV RNA 12 Weeks (SVR12) and 24 Weeks (SVR24) After Last Planned Dose of Study Treatment</outcome_measure>
      <outcome_measure>Effect of Efavirenz-based (EFV) and Atazanavir-based (ATV/r) Highly Active Antiretroviral Therapy(HAART) on Telaprevir Exposure</outcome_measure>
      <outcome_measure>Median Trough Plasma Concentration (Ctrough) Ratios of Efavirenz and Tenofovir (Part B Only, Subjects on EFV-based HAART)</outcome_measure>
      <outcome_measure>Median Trough Plasma Concentration (Ctrough) Ratios of Atazanavir (ATZ), Ritonavir, and Tenofovir (Part B Only, Subjects on ATV-based HAART)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00983853</url>
  </study>
  <study rank="42">
    <nct_id>NCT02087111</nct_id>
    <title>Telaprevir in Genotype 3 HCV</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">40 Kd Pegylated interferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Queen Mary University of London</lead_sponsor>
      <collaborator>Janssen-Cilag Ltd.</collaborator>
      <collaborator>Barts &amp; The London NHS Trust</collaborator>
      <collaborator>St George's Healthcare NHS Trust</collaborator>
      <collaborator>Bradford Teaching Hospitals NHS Foundation Trust</collaborator>
      <collaborator>Nottingham University Hospitals NHS Trust</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>9132</other_id>
      <other_id>2013-003729-27</other_id>
      <other_id>13/LO/1473</other_id>
    </other_ids>
    <first_received>March 12, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 11, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TIG3</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) 12 weeks after end of treatment (SVR12)</outcome_measure>
      <outcome_measure>Response rate prediction</outcome_measure>
      <outcome_measure>Sustained virological response 24 weeks after end of treatment.</outcome_measure>
      <outcome_measure>Treatment Success</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02087111</url>
  </study>
  <study rank="43">
    <nct_id>NCT01592006</nct_id>
    <title>Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-0156</other_id>
    </other_ids>
    <first_received>April 27, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>January 5, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>January 5, 2015</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Efficacy of Triple Antiviral Therapy</outcome_measure>
      <outcome_measure>Safety of Triple Antiviral Therapy in HCV Infected OLT Recipients</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01592006</url>
  </study>
  <study rank="44">
    <nct_id>NCT00758043</nct_id>
    <title>A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Nave Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>540</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX08-950-111</other_id>
      <other_id>EudraCT 2008-003836-39</other_id>
    </other_ids>
    <first_received>September 19, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>September 30, 2013</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24)</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have Undetectable HCV RNA at Week 72</outcome_measure>
      <outcome_measure>Proportion of Subjects Achieving eRVR (Extended RVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</outcome_measure>
      <outcome_measure>Proportion of Randomized Subjects Who Have Undetectable HCV RNA 12 Weeks After Last Dose of Study Treatment</outcome_measure>
      <outcome_measure>Proportion of Randomized Subjects Who Relapse, Defined as Those Who Complete Treatment, Have Undetectable HCV RNA at End of Treatment (EOT; Week 24 or Week 48 Respectively), and Become HCV RNA Detectable During Antiviral Follow-up</outcome_measure>
      <outcome_measure>Proportion of Enrolled Subjects Who Relapse, Defined as Those Who Have Undetectable HCV RNA at the EOT, and Become HCV RNA Detectable During Antiviral Follow-up</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have Undetectable HCV RNA at the EOT (Week 24 or Week 48 Respectively).</outcome_measure>
      <outcome_measure>Adverse Events, Physical Examination Findings, and Clinical Laboratory, Vital Sign, and Electrocardiogram (ECG) Assessments</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Netherlands</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00758043</url>
  </study>
  <study rank="45">
    <nct_id>NCT01415141</nct_id>
    <title>Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M11-219</other_id>
    </other_ids>
    <first_received>August 1, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response among subjects receiving a three drug versus two drug regimen of treatment</outcome_measure>
      <outcome_measure>Extended rapid virological response in patients receiving three drug versus two drug regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>Vermont</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01415141</url>
  </study>
  <study rank="46">
    <nct_id>NCT01275599</nct_id>
    <title>Drug-Drug Interaction Study Between Telaprevir and Buprenorphine</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">buprenorphine/naloxone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec BVBA</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX10-950-024</other_id>
    </other_ids>
    <first_received>January 11, 2011</first_received>
    <start_date>January 2011</start_date>
    <last_updated>June 7, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Blood levels of buprenorphine</outcome_measure>
      <outcome_measure>Blood levels of norbuprenorphine</outcome_measure>
      <outcome_measure>Blood levels of naloxone</outcome_measure>
      <outcome_measure>Blood levels of telaprevir</outcome_measure>
      <outcome_measure>Safety and tolerability</outcome_measure>
      <outcome_measure>Buprenorphine withdrawal symtoms</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Kansas</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01275599</url>
  </study>
  <study rank="47">
    <nct_id>NCT01492426</nct_id>
    <title>Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (Daclatasvir)</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>605</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-052</other_id>
      <other_id>2011-004237-14</other_id>
    </other_ids>
    <first_received>December 13, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>May 5, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COMMAND-3</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of genotype 1b patients with SVR12, defined as HCV RNA less than limit of quantitation at follow-up Week 12 in each group</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with hemoglobin value less than 10 g/dL</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with rash events</outcome_measure>
      <outcome_measure>Proportion of genotype1b patients with HCV RNA undetectable Week 12</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with HCV RNA undetectable Week 4</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with HCV RNA undetectable Weeks 4 and 12</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with SVR24, defined as HCV RNA &lt; Limit of Quantification (LOQ) at follow-up Week 24 for each cohort</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with SVR12 based on IL28B rs12979860 Single nucleotide polymorphism (SNP) genotype (CC or non-CC)</outcome_measure>
      <outcome_measure>Proportion of genotype 1a patients with SVR12 defined as HCV RNA &lt; LOQ at follow-up Week 12 for each cohort</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Brazil</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01492426</url>
  </study>
  <study rank="48">
    <nct_id>NCT02006745</nct_id>
    <title>An Open Label Trial of Pegylated Interferon, Ribavirin and Telaprevir Versus Pegylated Interferon and Ribavirin Alone in the Treatment of Hepatitis C Genotype 1 Virus Infection in Patients With HIV-1 Co-infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St Stephens Aids Trust</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SSAT 052</other_id>
    </other_ids>
    <first_received>December 5, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>October 9, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CHAT</acronym>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure> Comparison of rates of sustained virologic response(SVR24) between treatment arms; defined as HCV RNA not detectable at 24 weeks after planned completion of therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02006745</url>
  </study>
  <study rank="49">
    <nct_id>NCT00958152</nct_id>
    <title>Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VCH-222</intervention>
      <intervention type="Drug">VCH-222</intervention>
      <intervention type="Drug">VCH-222</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX09-222-002</other_id>
    </other_ids>
    <first_received>August 6, 2009</first_received>
    <start_date>August 2009</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>January 6, 2010</last_updated>
    <last_verified>January 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability based on vital signs, 12-lead electrocardiograms (ECGs), physical examination, laboratory assessments, and adverse events</outcome_measure>
      <outcome_measure>Pharmacokinetic parameters (Cmax, tmax, C12 h, Cmin, and AUC0-12 h) of VCH-222 at steady-state in plasma in the presence and absence of telaprevir at steady-state</outcome_measure>
      <outcome_measure>Pharmacokinetics parameters (Cmax, tmax, C12 h, Cmin, and AUC0-12 h) of telaprevir at steady-state in plasma in the presence and absence of VCH-222 at steady-state</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00958152</url>
  </study>
  <study rank="50">
    <nct_id>NCT01872936</nct_id>
    <title>Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Miravirsen</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Santaris Pharma A/S</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SPC3649-205</other_id>
    </other_ids>
    <first_received>June 3, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>November 17, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of subjects with a Sustained Virological Response at 24 weeks after the end of therapy.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV RNA levels at end of treatment.</outcome_measure>
      <outcome_measure>The proportion of subjects with a Sustained Virological Response at 12 and 48 weeks after the end of therapy.</outcome_measure>
      <outcome_measure>Change in HCV RNA levels from baseline throughout the study.</outcome_measure>
      <outcome_measure>The proportion of subjects who experience virological failure throughout the study.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01872936</url>
  </study>
  <study rank="51">
    <nct_id>NCT01818856</nct_id>
    <title>Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ritonavir withdrawal, atazanavir 200 mg/12h</intervention>
      <intervention type="Drug">Telaprevir interactions</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospitales Universitarios Virgen del Roco</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>LLC-TEL-2012-1</other_id>
      <other_id>2012-002515-25</other_id>
    </other_ids>
    <first_received>December 29, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>April 19, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in pharmacokinetic parameters of TVR</outcome_measure>
      <outcome_measure>Changes in pharmacokinetic parameters of ATV</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01818856</url>
  </study>
  <study rank="52">
    <nct_id>NCT01080222</nct_id>
    <title>A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Nave Subjects With Genotype 1 Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">VX-222</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon-alfa-2a</intervention>
      <intervention type="Drug">VX-222</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX09-222-103</other_id>
    </other_ids>
    <first_received>March 1, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>February 28, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Achieve a Sustained Viral Response</outcome_measure>
      <outcome_measure>Undetectable HCV RNA Measurements</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have a Viral Breakthrough or Relapse</outcome_measure>
      <outcome_measure>Plasma Exposures of VX-222 and Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01080222</url>
  </study>
  <study rank="53">
    <nct_id>NCT00973388</nct_id>
    <title>VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir; Moxifloxacin; Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016417</other_id>
    </other_ids>
    <first_received>September 4, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>December 16, 2010</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective is to evaluate the effect of administration of TVR 750 mg every 8 hours and 1875 mg every 8 hours, both at steady-state, versus placebo on the QT and QTc interval (heart activity) in healthy volunteers.</outcome_measure>
      <outcome_measure>Trial sensitivity will be evaluated (i.e., the effect of a positive control, a single 400 mg dose of moxifloxacin, on the QT/QTc interval).</outcome_measure>
      <outcome_measure>The effect of 2 different regimens of TVR on non-QT interval electrocardiogram (ECG) parameters (RR interval, HR, PR interval, and QRS interval) will be evaluated.</outcome_measure>
      <outcome_measure>The pharmacokinetics of 2 dose regimens of TVR, 750 mg every 8 hours and 1875 mg every 8 hours, at steady-state will be evaluated.</outcome_measure>
      <outcome_measure>The concentration-effect relationship for QT/QTc for TVR will be explored.</outcome_measure>
      <outcome_measure>The short-term safety and tolerability of 2 dose regimens of TVR, 750 mg and 1875 mg every 8 hours will be evaluated.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00973388</url>
  </study>
  <study rank="54">
    <nct_id>NCT01701063</nct_id>
    <title>An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Janssen Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-118</other_id>
    </other_ids>
    <first_received>September 27, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>May 12, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety parameters, including AEs, study drug modifications or discontinuations, clinical laboratory values, vital signs, and electrocardiogram (ECG) assessments</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve undetectable HCV RNA 12 weeks after the last planned dose of study drug (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve undetectable HCV RNA 24 weeks after the last planned dose of study drug (SVR24)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve undetectable HCV RNA at Week 4, at Week 12, at both Weeks 4 and 12 (eRVR), and at the planned end of treatment (EOT)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment virologic failure, defined as either meeting a futility rule or completing the assigned treatment duration with detectable HCV RNA at the EOT</outcome_measure>
      <outcome_measure>Proportion of subjects with virological relapse, defined as having undetectable HCV RNA at planned EOT followed by detectable HCV RNA after planned EOT</outcome_measure>
      <outcome_measure>Part A only, then Part B: Composite of Pharmacokinetics of telaprevir</outcome_measure>
      <outcome_measure>Changes from baseline in the amino acid sequence of the HCV NS34A protease</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01701063</url>
  </study>
  <study rank="55">
    <nct_id>NCT01718145</nct_id>
    <title>A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">pegIFN-2b</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>258</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-031</other_id>
    </other_ids>
    <first_received>October 29, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with SVR12, defined as HCV RNA target detected or target not detected below LLOQ in the naive cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with hemoglobin &lt; 10g/dL</outcome_measure>
      <outcome_measure>Proportion of subjects with rash-related dermatologic events</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target detected or target not detected below LLOQ in the naive cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target not detected in the naive cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12, defined as HCV RNA target detected or target not detected below LLOQ in the relapser cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target detected or target not detected below LLOQ in the relapser cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target not detected in the relapser cohort</outcome_measure>
      <outcome_measure>On treatment safety, as measured by the frequency of Severe adverse events (SAEs), discontinuation and dose modification/interruption due to Adverse events (AEs), Grade 3-4 abnormalities observed from clinical laboratory tests for each treatment group</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01718145</url>
  </study>
  <study rank="56">
    <nct_id>NCT00535847</nct_id>
    <title>A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec, Inc</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX06-950-107</other_id>
    </other_ids>
    <first_received>September 25, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>July 9, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Percentage of Prior Relapsers With Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Subjects With End of Treatment Response</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable HCV RNA at Week 48 After Completion of Treatment Among Subjects Who Completed Assigned Treatment</outcome_measure>
      <outcome_measure>Cross Tabulation of Extended Rapid Viral Response (eRVR) and Sustained Viral Response (SVR) in With Prior Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Puerto Rico</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00535847</url>
  </study>
  <study rank="57">
    <nct_id>NCT00933894</nct_id>
    <title>VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir; Escitalopram</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016303</other_id>
    </other_ids>
    <first_received>July 2, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>December 16, 2010</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants and vica versa.</outcome_measure>
      <outcome_measure>The short-term safety and tolerability of coadministration of TVR and escitalopram in healthy participants</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00933894</url>
  </study>
  <study rank="58">
    <nct_id>NCT00828789</nct_id>
    <title>VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HCV</condition>
      <condition>HIV</condition>
      <condition>AIDS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Efavirenz; Tenofovir disoproxil fumarate; Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015790</other_id>
    </other_ids>
    <first_received>January 22, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>December 16, 2010</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objectives are to determine the effect of EFV and TDF on the pharmacokinetics of TVR and VRT-127394 and of TVR every 8h and every 12h on the pharmacokinetics of EFV and TDF.</outcome_measure>
      <outcome_measure>The secondary objective is to determine the short-term safety and tolerability of the coadministration of TVR, EFV and TDF.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00828789</url>
  </study>
  <study rank="59">
    <nct_id>NCT01598090</nct_id>
    <title>Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon Lambda-1a</intervention>
      <intervention type="Biological">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>636</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-020</other_id>
      <other_id>2011-004695-11</other_id>
    </other_ids>
    <first_received>May 9, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEDESTAL</acronym>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A: Proportion of subjects achieving efficacy as measured by Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Part A: Safety as measured by the frequency of deaths, Serious Adverse Events (SAEs), drug related Adverse Events (AEs), dose reductions and discontinuations due to AEs</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects achieving efficacy as measured by Sustained Virologic Response at post-treatment Week12 (SVR 12) defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part A: Proportion of subjects who achieve efficacy as measured by SVR12, defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part A: Proportion of subjects who achieve efficacy as measured by SVR24, defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects who achieve efficacy as measured by SVR12, defined as hepatitis C virus (HCV) RNA &lt; 25 IU/ml in treatment-naive subjects</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects who achieve efficacy as measured by eRVR, defined as HCV RNA undetectable</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects who achieve efficacy as measured by SVR 24, defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part B: Number of incidence for Cytopenic abnormalities (anemia is defined by Hb &lt; 10 g/dL, neutropenia as defined by ANC &lt; 750 mm3, thrombocytopenia as defined by platelets &lt; 50,000 mm3)</outcome_measure>
      <outcome_measure>Part B: Number of incidence for Flu-like symptoms (as defined by pyrexia or chills or pain)</outcome_measure>
      <outcome_measure>Part B: Number of incidence for Musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01598090</url>
  </study>
  <study rank="60">
    <nct_id>NCT01716403</nct_id>
    <title>Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>C Hepatitis, Tri Therapy</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Grenoble</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1211</other_id>
    </other_ids>
    <first_received>October 25, 2012</first_received>
    <start_date>October 2012</start_date>
    <last_updated>January 25, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Ribatela</acronym>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>telaprevir concentration and area under the curve</outcome_measure>
      <outcome_measure>ribavirin concentration and area under the curve</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01716403</url>
  </study>
  <study rank="61">
    <nct_id>NCT01718158</nct_id>
    <title>Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment nave Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon Lambda-1a</intervention>
      <intervention type="Biological">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>444</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-021</other_id>
      <other_id>201100540965</other_id>
    </other_ids>
    <first_received>October 29, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>STRUCTURE</acronym>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at post-treatment follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR12 in treatment-naive subjects</outcome_measure>
      <outcome_measure>Proportion of subjects with rash related dermatologic events</outcome_measure>
      <outcome_measure>Proportion of subjects who develop treatment emergent cytopenic abnormalities</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment interferon (IFN) associated flu like/musculoskeletal symptoms</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR24 [Hepatitis C virus (HCV) Ribonucleic acid (RNA) &lt; Lower limit of quantitation (LLOQ)] at post-treatment follow-up Week 24</outcome_measure>
      <outcome_measure>Proportion of subjects with adverse events (AEs), Serious adverse events (SAEs), dose reductions, and discontinuations due to AEs through end of follow-up</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR12 with a 24-week treatment regimen</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Extended rapid virologic response (eRVR) (HCV RNA &lt; LLOQ target not detected at Weeks 4 and 12 of treatment)</outcome_measure>
      <outcome_measure>Patient Health Questionnaire-9 (PHQ-9) score through end of follow-up</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent laboratory abnormalities by toxicity grade through End of treatment (EOT)</outcome_measure>
      <outcome_measure>Proportion of subjects with the following on-treatment interferon-associated neuropsychiatric symptoms through EOT</outcome_measure>
      <outcome_measure>Association of Single nucleotide polymorphism (SNPs) in Interleukin 28B (IL28B) (including rs12979860) or equilibrative nucleoside transporter 1 (ENT1) with clinical responses</outcome_measure>
      <outcome_measure>Resistant variants associated with virologic failure through end of follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>Korea, Republic of</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Georgia</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01718158</url>
  </study>
  <study rank="62">
    <nct_id>NCT01854697</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated Interferon alpha 2-alpha (PegIFN)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>311</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-774</other_id>
      <other_id>2012-003754-84</other_id>
    </other_ids>
    <first_received>April 8, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>July 20, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MALACHITE 1</acronym>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The percentage of all dosed subjects with sustained virologic response following the last actual dose of study drug.</outcome_measure>
      <outcome_measure>Change in general health-related quality of life using the Short-Form 36 Version 2 health status survey (SF-36V2) Mental Component Summary (MCS)</outcome_measure>
      <outcome_measure>Change in general health-related quality of life using the SF-36V2 Physical Component Summary (PCS) scores</outcome_measure>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic failures during treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with post-treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Chile</country>
      <country>Finland</country>
      <country>Hungary</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Slovakia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01854697</url>
  </study>
  <study rank="63">
    <nct_id>NCT01482390</nct_id>
    <title>A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">mericitabine</intervention>
      <intervention type="Drug">mericitabine</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV27779</other_id>
      <other_id>2011-002715-28</other_id>
    </other_ids>
    <first_received>November 28, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>March 9, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 12 weeks after treatment (SVR-12)</outcome_measure>
      <outcome_measure>Sustained virological response 4 weeks after treatment (SVR-4)</outcome_measure>
      <outcome_measure>Virologic response over time</outcome_measure>
      <outcome_measure>Proportion of patients who develop treatment resistance</outcome_measure>
      <outcome_measure>Safety (incidence of adverse events)</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO4995855</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO5012433</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01482390</url>
  </study>
  <study rank="64">
    <nct_id>NCT01766115</nct_id>
    <title>Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Viral Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2012P000954</other_id>
    </other_ids>
    <first_received>January 7, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>August 12, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Election rate of study drug</outcome_measure>
      <outcome_measure>Rate of HCV infection</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Massachusetts</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01766115</url>
  </study>
  <study rank="65">
    <nct_id>NCT01858961</nct_id>
    <title>Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1241.37</other_id>
      <other_id>2012-004544-30</other_id>
    </other_ids>
    <first_received>May 17, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>January 22, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response at Week 12 after end of treatment (SVR12)</outcome_measure>
      <outcome_measure>SVR4: Plasma HCV RNA level &lt;25 IU/mL1 at 4 weeks after end of treatment</outcome_measure>
      <outcome_measure>SVR24: Plasma HCV RNA level &lt;25 IU/mL1 at 24 weeks after end of treatment</outcome_measure>
      <outcome_measure>Virological Response at Week 4 -Plasma HCV RNA level undetectable at Week 4 -Plasma HCV RNA level &lt;25 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Plasma HCV level undetectable at Week 12</outcome_measure>
      <outcome_measure>Time to achieving HCV RNA undetectable</outcome_measure>
      <outcome_measure>Virological breakthrough</outcome_measure>
      <outcome_measure>ETR: Plasma HCV RNA level undetected at the end of treatment</outcome_measure>
      <outcome_measure>Lack of on-treatment viral response</outcome_measure>
      <outcome_measure>Relapse</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Adverse events leading to discontinuation</outcome_measure>
      <outcome_measure>Serious Adverse Events</outcome_measure>
      <outcome_measure>Laboratory test abnormalities by DAIDS grades</outcome_measure>
      <outcome_measure>Rate of red blood cell transfusion</outcome_measure>
      <outcome_measure>Time to discontinuation of trial medication</outcome_measure>
      <outcome_measure>Liver disease progression, fibroscan and FibroSURE</outcome_measure>
      <outcome_measure>Rate of ESA use</outcome_measure>
      <outcome_measure>Change in laboratory test values over time</outcome_measure>
      <outcome_measure>Patients requiring hospitalisation due to AEs related to study drugs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>Spain</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01858961</url>
  </study>
  <study rank="66">
    <nct_id>NCT01854528</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavrin</intervention>
      <intervention type="Drug">Pegylated Interferon alpha 2-alpha (PegINF)</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>154</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-862</other_id>
      <other_id>2012-003738-18</other_id>
    </other_ids>
    <first_received>May 13, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>July 29, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Change in Mental Component Summary (MCS) of the SF-36 v.2</outcome_measure>
      <outcome_measure>Change in Physical Component Summary (PCS) of the SF-36 v.2</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with post-treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Chile</country>
      <country>Finland</country>
      <country>Hungary</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Slovakia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01854528</url>
  </study>
  <study rank="67">
    <nct_id>NCT01786382</nct_id>
    <title>A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pharmacokinetic Assessments in Healthy Volunteers</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PPI-668</intervention>
      <intervention type="Drug">Midazolam</intervention>
      <intervention type="Drug">Omeprazole</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Presidio Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PPI-668-102</other_id>
    </other_ids>
    <first_received>February 4, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>March 22, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Midazolam area under the plasma concentration-time curve from time 0 to 24 hours after dosing (AUC0-24)</outcome_measure>
      <outcome_measure>Midazolam maximum observed plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>Omeprazole area under the plasma concentration-time curve from time 0 to 24 hours after dosing (AUC0-24)</outcome_measure>
      <outcome_measure>Omeprazole maximum observed plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>Telaprevir area under the plasma concentration-time curve from time 0 to 24 hours after dosing (AUC0-24)</outcome_measure>
      <outcome_measure>Telaprevir maximum observed plasma concentration (Cmax)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01786382</url>
  </study>
  <study rank="68">
    <nct_id>NCT01581138</nct_id>
    <title>VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-222</intervention>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-222-108</other_id>
    </other_ids>
    <first_received>April 17, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>July 2, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of subjects who have a sustained viral response (SVR) at 12 weeks after the last planned dose of treatment</outcome_measure>
      <outcome_measure>The safety and tolerability as assessed by adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), and laboratory assessments (serum chemistry, hematology, and urinalysis)</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR 24 weeks after the last planned dose of the study drug</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR 4 weeks after the last planned dose of the study drug</outcome_measure>
      <outcome_measure>The proportion of subjects who relapse (i.e., who had &lt;lower limit of quantitation LLOQ hepatitis C virus (HCV) RNA at the end of planned study drug treatment (planned EOT) followed by LLOQ HCV RNA after planned EOT)</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve undetectable HCV RNA (below the lower limit of detection (&lt; (LLOQ) undetectable) at Weeks 2, 4, 8, 12, and 16 after the first dose of study drug, and &lt;LLOQ at the end of planned study drug treatment (planned EOT)</outcome_measure>
      <outcome_measure>Time to achieve &lt;LLOQ undetectable HCV RNA</outcome_measure>
      <outcome_measure>The proportion of subjects who have on-treatment virologic failure defined as subjects who either have viral breakthrough or who complete the assigned treatment and have LLOQ HCV RNA at the end of study drug treatment (EOT)</outcome_measure>
      <outcome_measure>The association of the interleukin-28B (IL-28B) genotype (CC versus CT versus TT) with SVR12</outcome_measure>
      <outcome_measure>The amino acid sequence of the nonstructural (NS)3/4A and NS5B proteins in subjects who have treatment failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01581138</url>
  </study>
  <study rank="69">
    <nct_id>NCT01980290</nct_id>
    <title>Telaprevir With Peginterferon Alfa &amp; Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutica N.V., Belgium</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100966</other_id>
      <other_id>VX-950HPC4017</other_id>
    </other_ids>
    <first_received>November 4, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>March 6, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>INTEGRATE</acronym>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response at 12 weeks (SVR12)</outcome_measure>
      <outcome_measure>adherence to telaprevir until Week 12</outcome_measure>
      <outcome_measure>adherence to PegIFN alfa and RBV</outcome_measure>
      <outcome_measure>on-treatment virologic response undetectable</outcome_measure>
      <outcome_measure>on treatment virologic response</outcome_measure>
      <outcome_measure>health-related quality of life based on EQ-5D</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale (HADS)</outcome_measure>
      <outcome_measure>alcohol use disorders identification test (AUDIT)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01980290</url>
  </study>
  <study rank="70">
    <nct_id>NCT01563328</nct_id>
    <title>A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection, Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DTG</intervention>
      <intervention type="Drug">BCV</intervention>
      <intervention type="Drug">TVR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ViiV Healthcare</lead_sponsor>
      <collaborator>Shionogi</collaborator>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>115697</other_id>
    </other_ids>
    <first_received>March 22, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>May 31, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Plasma steady-state DTG PK parameters AUC(0-), Cmax, Cmin, and C</outcome_measure>
      <outcome_measure>Safety and tolerability parameters as assessed by change from baseline in vital signs n(BP and HR), number of subjects with adverse events and toxicity grading of clinical laboratory tests.</outcome_measure>
      <outcome_measure>Plasma steady-state DTG tmax and t1/2</outcome_measure>
      <outcome_measure>Plasma steady-state TVR and BCV AUC(0-t), Cmax, Cmin, and Ct</outcome_measure>
      <outcome_measure>Plasma steady-state TVR and BCV tmax and t1/2</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01563328</url>
  </study>
  <study rank="71">
    <nct_id>NCT01582035</nct_id>
    <title>Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">TVR</intervention>
      <intervention type="Drug">TVR</intervention>
      <intervention type="Drug">TVR</intervention>
      <intervention type="Drug">PegFN</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100735</other_id>
      <other_id>TMC647055HPC1005</other_id>
      <other_id>2011-004028-37</other_id>
    </other_ids>
    <first_received>April 19, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>February 14, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Plasma PK parameters for TMC647055 and TVR after combination therapy in panel 1 and 2.</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability.</outcome_measure>
      <outcome_measure>Change from baseline values for clinical laboratory tests.</outcome_measure>
      <outcome_measure>Change from baseline values for ECG and vital signs.</outcome_measure>
      <outcome_measure>Change from baseline for physical examination.</outcome_measure>
      <outcome_measure>Individual evalution of HCV RNA levels.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01582035</url>
  </study>
  <study rank="72">
    <nct_id>NCT01704521</nct_id>
    <title>Viral Kinetics in HCV Clearance in Subjects With Hemophilia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hemophilia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegInterferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kenneth Sherman</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
      <collaborator>Genentech, Inc.</collaborator>
      <collaborator>University of Cincinnati</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>12053004</other_id>
      <other_id>R34HL109334</other_id>
    </other_ids>
    <first_received>October 5, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>March 26, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>February 3, 2015</firstreceived_results_date>
    <acronym>HCV/Hemophil</acronym>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virological Response at Week 12 (SVR12)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01704521</url>
  </study>
  <study rank="73">
    <nct_id>NCT01532908</nct_id>
    <title>Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">MBL-HCV1</intervention>
      <intervention type="Drug">Telaprevir (Part 1)</intervention>
      <intervention type="Drug">Sofosbuvir (Part 2)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MassBiologics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MBL-HCV1-11-03</other_id>
    </other_ids>
    <first_received>February 10, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>January 12, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MBL-HCV1</acronym>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of subjects with undetectable HCV RNA at day 56</outcome_measure>
      <outcome_measure>Evaluate the safety and tolerability as assessed by adverse events, concomitant medication use, physical examination, clinical laboratory evaluation</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV RNA at multiple time points through at least 6 weeks after end of treatment</outcome_measure>
      <outcome_measure>Evaluate the reduction in viral load as compared with pre-transplant HCV RNA levels</outcome_measure>
      <outcome_measure>Determine HCV resistance-associated variants to MBL-HCV1 and oral direct-acting antivirals before and after receipt of study treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01532908</url>
  </study>
  <study rank="74">
    <nct_id>NCT01641094</nct_id>
    <title>Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
      <collaborator>Janssen-Cilag B.V.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ETIM</other_id>
    </other_ids>
    <first_received>July 12, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>March 10, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ETIM</acronym>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determine functionality of immune cells in the liver and blood in chronic HCV patients before, during and after treatment with telaprevir, pegylated-IFN-a and ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01641094</url>
  </study>
  <study rank="75">
    <nct_id>NCT01514890</nct_id>
    <title>French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>675</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS CO20</other_id>
      <other_id>2010-A01273-36</other_id>
    </other_ids>
    <first_received>January 18, 2012</first_received>
    <start_date>February 2011</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>December 26, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CUPIC</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of sustained virological response (SVR) defined by an undetectable RNA by real-time PCR.</outcome_measure>
      <outcome_measure>Virological response during and after the treatment with determination of HCV RNA levels as prevised by the French Early Access Program for the use of protease inhibitors and after the approval.</outcome_measure>
      <outcome_measure>early viral kinetic</outcome_measure>
      <outcome_measure>Rate of premature discontinuation of protease inhibitor, RBV and/or PEG-IFN</outcome_measure>
      <outcome_measure>occurrence of resistant mutants in partial responders (detectable RNA) or after the occurrence of virological breakthrough and long term evolution of these mutations (on serum bank)</outcome_measure>
      <outcome_measure>Evolution of quality of life scores</outcome_measure>
      <outcome_measure>Evaluation of therapeutic observance with auto-questionnaires</outcome_measure>
      <outcome_measure>Rate of adaptation of dosage of protease inhibitors, RBV and/or PEG-IFN</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01514890</url>
  </study>
  <study rank="76">
    <nct_id>NCT01743521</nct_id>
    <title>DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Early Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TPV/PEG-IFN/RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
      <collaborator>Janssen-Cilag Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1102</other_id>
      <other_id>VX-950HCP4010</other_id>
    </other_ids>
    <first_received>November 28, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>August 31, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DARE-C</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
      <outcome_measure>Undetectable HCV RNA (ETR)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA (weeks 1,2,3,4,5,6,8)</outcome_measure>
      <outcome_measure>gene IL28B polymorphism</outcome_measure>
      <outcome_measure>Baseline resistance-associated variants</outcome_measure>
      <outcome_measure>Resistance-associated variants</outcome_measure>
      <outcome_measure>Indicators of toxicity (ALT, HB, Neutrophils, Platelets)</outcome_measure>
      <outcome_measure>Plasma ribavirin levels and haemoglobin</outcome_measure>
      <outcome_measure>CD4 and HIV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01743521</url>
  </study>
  <study rank="77">
    <nct_id>NCT00251199</nct_id>
    <title>VX-950 and Peginterferon for Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-950</intervention>
      <intervention type="Drug">peginterferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX05-950-103</other_id>
    </other_ids>
    <first_received>November 7, 2005</first_received>
    <start_date>October 2005</start_date>
    <completion_date>March 2006</completion_date>
    <last_updated>December 17, 2007</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Viral kinetics</outcome_measure>
      <outcome_measure>Assess the safety of VX-950 in combination with peginterferon</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00251199</url>
  </study>
  <study rank="78">
    <nct_id>NCT00262483</nct_id>
    <title>Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-950</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX05-950-102</other_id>
    </other_ids>
    <first_received>December 2, 2005</first_received>
    <start_date>December 2005</start_date>
    <completion_date>April 2006</completion_date>
    <last_updated>December 17, 2007</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Safety of triple combination therapy.</outcome_measure>
      <outcome_measure>Pharmacokinetics of VX-950, peginterferon alfa-2a and ribavirin.</outcome_measure>
      <outcome_measure>Plasma HCV RNA levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00262483</url>
  </study>
  <study rank="79">
    <nct_id>NCT01648140</nct_id>
    <title>Dose Ranging of GSK2336805 in Combination Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK2336805 40 mg</intervention>
      <intervention type="Drug">GSK2336805 60 mg</intervention>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
      <collaborator>PPD</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>286</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>115879</other_id>
    </other_ids>
    <first_received>July 12, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>September 10, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HAI115879</acronym>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Frequency of adverse events and absolute values.</outcome_measure>
      <outcome_measure>Antiviral activity of 40 and 60 mg of GSK2336805 when given in combination with pegylated interferon alpha-2a and ribavirin.</outcome_measure>
      <outcome_measure>Changes over time from predose values for hematology, clinical chemistry, urinalysis, vital sign measurements and electrocardiograms.</outcome_measure>
      <outcome_measure>GSK2336805 plasma pharmacokinetics</outcome_measure>
      <outcome_measure>Very rapid virologic response (vRVR)</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Complete early virologic response (cEVR)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR12)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR24)</outcome_measure>
      <outcome_measure>Sustained virologic response rates between GSK2336805 and standard of care</outcome_measure>
      <outcome_measure>Resistance against GSK2336805</outcome_measure>
      <outcome_measure>Antiviral activity and safety of 60 mg of GSK2336805 in subjects with genotype 4 hepatitis C virus (HCV) infection</outcome_measure>
      <outcome_measure>GSK2336805 exposure-response relationships</outcome_measure>
      <outcome_measure>Frequency of adverse events and absolute values</outcome_measure>
      <outcome_measure>Changes over time from predose values for hematology, clinical chemistry, urinalysis, vital sign measurements and electrocardiograms</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Bulgaria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Nevada</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01648140</url>
  </study>
  <study rank="80">
    <nct_id>NCT00509210</nct_id>
    <title>Study of Telaprevir in Subjects With Hepatic Impairment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatic Insufficiency</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir (VX-950)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX06-950-012</other_id>
    </other_ids>
    <first_received>July 30, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>October 28, 2008</last_updated>
    <last_verified>October 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetics</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Indiana</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00509210</url>
  </study>
  <study rank="81">
    <nct_id>NCT01577069</nct_id>
    <title>Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Association HGE CHU Bordeaux Sud</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>73</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>UDPS-100211</other_id>
    </other_ids>
    <first_received>April 12, 2012</first_received>
    <start_date>February 2011</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>July 29, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>GENUPI</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>virological resitance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01577069</url>
  </study>
  <study rank="82">
    <nct_id>NCT02452814</nct_id>
    <title>Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP29710</other_id>
    </other_ids>
    <first_received>May 11, 2015</first_received>
    <start_date>May 2014</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with adverse changes in liver ultrasound results</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02452814</url>
  </study>
  <study rank="83">
    <nct_id>NCT02004379</nct_id>
    <title>Register of Telaprevir and Boceprevir in Routine Clinical Practice</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Fundacin Pblica Andaluza Progreso y Salud</lead_sponsor>
      <collaborator>Andalusian Initiative for Advanced Therapies - Fundacin Pblica Andaluza Progreso y Salud</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1553</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>FPS-TEL-2013-01</other_id>
    </other_ids>
    <first_received>November 20, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 14, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effectiveness of current treatment of hepatitis C virus, genotype 1, for patients who have never been treated and for patients who have been previously treated</outcome_measure>
      <outcome_measure>Safety of current treatment of hepatitis C virus, genotype 1, for patients who have never been treated and for patients who have been previously treated</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02004379</url>
  </study>
  <study rank="84">
    <nct_id>NCT00630058</nct_id>
    <title>A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424(H), PEG-IFN-a-2b, RBV</intervention>
      <intervention type="Drug">MP-424 (L), PEG-IFN-a-2b, RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A5</other_id>
    </other_ids>
    <first_received>February 24, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>December 12, 2012</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cmax (Maximum Observed Concentration in Plasma) of MP-424</outcome_measure>
      <outcome_measure>Tmax (Time of Maximum Concentration in Plasma) of MP-424</outcome_measure>
      <outcome_measure>AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424</outcome_measure>
      <outcome_measure>Ctrough (Minimum Observed Concentration in Plasma) of MP-424</outcome_measure>
      <outcome_measure>T1/2(Time of Half-Life) of MP-424</outcome_measure>
      <outcome_measure>Antiviral Effects of TVR on HCV Were Assessed by Measuring Plasma HCV RNA Levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00630058</url>
  </study>
  <study rank="85">
    <nct_id>NCT00621296</nct_id>
    <title>Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424 (Telaprevir)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A7</other_id>
    </other_ids>
    <first_received>February 12, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>September 19, 2012</firstreceived_results_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00621296</url>
  </study>
  <study rank="86">
    <nct_id>NCT01544582</nct_id>
    <title>Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>719</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08518</other_id>
      <other_id>EP08043.001</other_id>
      <other_id>SCH 503034 P08518</other_id>
    </other_ids>
    <first_received>February 2, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>June 30, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Boceprevir utilization versus other therapies</outcome_measure>
      <outcome_measure>Clinical management of health outcomes of interest ([HOI], anemia, neutropenia, thrombocytopenia, or serious rash)</outcome_measure>
      <outcome_measure>Incidence of anemia, neutropenia, thrombocytopenia, and serious skin rash</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01544582</url>
  </study>
  <study rank="87">
    <nct_id>NCT02057003</nct_id>
    <title>Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAA against HCV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
      <collaborator>Hospital Universitario Reina Sofia</collaborator>
      <collaborator>Hospital Universitario Virgen de la Victoria</collaborator>
      <collaborator>Hospital Universitario de la Princesa</collaborator>
      <collaborator>Hospitales Universitarios Virgen del Roco</collaborator>
      <collaborator>Hospital Universitario Carlos Haya</collaborator>
      <collaborator>Hospital Torrecrdenas</collaborator>
      <collaborator>Complejo Hospitalario Universitario de Huelva</collaborator>
      <collaborator>Hospital Puerta del Mar</collaborator>
      <collaborator>Hospital Universitario Virgen Macarena</collaborator>
      <collaborator>Hospital de La Lnea</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPAVIR-DAA</other_id>
    </other_ids>
    <first_received>January 6, 2014</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients who achieve SVR to DAA-based therapy as measure of efficacy</outcome_measure>
      <outcome_measure>Number of patients who develop severe adverse events as measure of safety</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to a BOC-based regimen as compared to numbers of patients who achieve SVR to a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who reach undetectable HCV-RNA at week 4 of PI-based therapy as a measure of on-treatment response to therapy.</outcome_measure>
      <outcome_measure>Number of patients who develop adverse events during a BOC-based regimen as compared to numbers of patients who develop adverse events during a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to an interferon-free regimen.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02057003</url>
  </study>
  <study rank="88">
    <nct_id>NCT00780416</nct_id>
    <title>Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Nave Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>189</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A6</other_id>
    </other_ids>
    <first_received>October 24, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>June 5, 2012</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00780416</url>
  </study>
  <study rank="89">
    <nct_id>NCT01485991</nct_id>
    <title>TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINF-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINF-2a and Ribavirin Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">TVR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>771</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100677</other_id>
      <other_id>TMC435HPC3001</other_id>
    </other_ids>
    <first_received>November 25, 2011</first_received>
    <start_date>February 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>March 27, 2015</firstreceived_results_date>
    <acronym>ATTAIN</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>Czech Republic</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Hungary</country>
      <country>Israel</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>Montana</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01485991</url>
  </study>
  <study rank="90">
    <nct_id>NCT01691235</nct_id>
    <title>SIMpill Medication Dispensing Device in the Treatment of HCV</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Device">SIMpill device</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-1293</other_id>
    </other_ids>
    <first_received>September 17, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>October 6, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SIMpill HCV</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improved SVR Rates</outcome_measure>
      <outcome_measure>Improved Patient Adherence Rates</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01691235</url>
  </study>
  <study rank="91">
    <nct_id>NCT02333292</nct_id>
    <title>Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">SMV</intervention>
      <intervention type="Drug">DCV</intervention>
      <intervention type="Drug">LED</intervention>
      <intervention type="Drug">PTV/OTV</intervention>
      <intervention type="Drug">DBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GEHEP-MONO</other_id>
    </other_ids>
    <first_received>December 15, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>FPSMON201401</acronym>
    <primary_completion_date>November 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Patients with Sustained Virological Response</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events</outcome_measure>
      <outcome_measure>Identification of predictors of SVR</outcome_measure>
      <outcome_measure>Analyze efficacy and safety in patients that receive methadone maintenance therapy</outcome_measure>
      <outcome_measure>Analyze efficacy and safety according to previous treatment outcome</outcome_measure>
      <outcome_measure>Analyze efficacy and safety in patients with cirrhosis</outcome_measure>
      <outcome_measure>Evaluate impact of SVR on biological, elastographical and clinical parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02333292</url>
  </study>
  <study rank="92">
    <nct_id>NCT00781274</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A9</other_id>
    </other_ids>
    <first_received>October 24, 2008</first_received>
    <start_date>December 2008</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>June 5, 2012</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00781274</url>
  </study>
  <study rank="93">
    <nct_id>NCT00780910</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>109</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A8</other_id>
    </other_ids>
    <first_received>October 24, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>June 5, 2012</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00780910</url>
  </study>
  <study rank="94">
    <nct_id>NCT00591214</nct_id>
    <title>Safety and PK Study of MP-424 to Treat Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424 (Telaprevir)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A3</other_id>
    </other_ids>
    <first_received>December 26, 2007</first_received>
    <start_date>December 2007</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>April 15, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>September 19, 2012</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cmax (Maximum Observed Concentration in Plasma) of MP-424</outcome_measure>
      <outcome_measure>Tmax (Time of Maximum Plasma Concentration) of MP-424</outcome_measure>
      <outcome_measure>AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424</outcome_measure>
      <outcome_measure>Ctrough (Plasma Trough Concentration) of MP-424</outcome_measure>
      <outcome_measure>t1/2 (Half Life Period) of MP-424</outcome_measure>
      <outcome_measure>Change in HCV RNA Levels of MP-424</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00591214</url>
  </study>
  <study rank="95">
    <nct_id>NCT01468584</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424 (generic name:Telaprevir)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A11</other_id>
    </other_ids>
    <first_received>November 2, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>October 29, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 29, 2014</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01468584</url>
  </study>
  <study rank="96">
    <nct_id>NCT01466192</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424 (generic name:Telaprevir)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A10</other_id>
    </other_ids>
    <first_received>November 2, 2011</first_received>
    <start_date>May 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 29, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 29, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01466192</url>
  </study>
  <study rank="97">
    <nct_id>NCT01816490</nct_id>
    <title>THISTLE - The HIV-HCV Silibinin Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Intravenous Silibinin (iSIL)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>THISTLE</other_id>
    </other_ids>
    <first_received>March 8, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>March 4, 2015</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>THISTLE</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Frequency of adverse events during iSIL treatment.</outcome_measure>
      <outcome_measure>Kinetics of the decline in HCV-RNA after 2 weeks of iSIL treatment (difference in IU/ml from day 1 to day 15).</outcome_measure>
      <outcome_measure>Drug levels of iSIL and its influence on the drug-level of co-administrated ART.</outcome_measure>
      <outcome_measure>Proportion of patients with HIV virological failure, i.e. confirmed viremia &gt;50cp/ml.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01816490</url>
  </study>
  <study rank="98">
    <nct_id>NCT01771653</nct_id>
    <title>Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Southern Illinois University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>KOI-SIUSOM-12-002</other_id>
    </other_ids>
    <first_received>January 16, 2013</first_received>
    <start_date>September 2011</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>August 5, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virologic Response</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Effect of baseline variables on treatment outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01771653</url>
  </study>
  <study rank="99">
    <nct_id>NCT01604291</nct_id>
    <title>An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
      <collaborator>Clalit Health Services</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>959</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28268</other_id>
    </other_ids>
    <first_received>May 21, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)-24 rate: Percentage of patients with HCV RNA &lt;50 IU/mL at 24 weeks post completion of treatment</outcome_measure>
      <outcome_measure>Dual versus triple Pegasys-based therapy: SVR-24 rates</outcome_measure>
      <outcome_measure>Correlation between SVR-24 and clinical/demographic baseline values</outcome_measure>
      <outcome_measure>Predictive value of on-treatment factors (RVR, eRVR, EVR, EOT) on virological response (HCV-RNA &lt;50 IU/mL): Percentage of patients with rapid/rapid extended/early/end of treatment response</outcome_measure>
      <outcome_measure>Treatment duration</outcome_measure>
      <outcome_measure>Dose reductions/treatment discontinuations</outcome_measure>
      <outcome_measure>Correlation between dose reductions/treatment interruptions and sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events (dual versus triple therapy)</outcome_measure>
      <outcome_measure>Rate of treatment-induced anemia (dual versus triple therapy)</outcome_measure>
      <outcome_measure>Treatment regimens for HCV treatment induced anemia in routine clinical practice</outcome_measure>
      <outcome_measure>Rate of virological relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01604291</url>
  </study>
  <study rank="100">
    <nct_id>NCT01359644</nct_id>
    <title>Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PSI-7977</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Pharmasset</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-040</other_id>
    </other_ids>
    <first_received>May 23, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 21, 2015</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post Treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post Treatment Week 24 (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough During the Treatment Period</outcome_measure>
      <outcome_measure>Percentage of Participants Who Experienced Viral Relapse During Follow-up Period</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) RNA at Follow-up Week 24</outcome_measure>
      <outcome_measure>Number of Participants Who Died and With Serious Adverse Events (SAEs) and Grade 3-4 Adverse Events (AEs), During the Treatment Period Prior to Addition of Rescue Therapy</outcome_measure>
      <outcome_measure>Number of Participants Who Died and With Serious Adverse Events (SAEs), Grade 3-4 Adverse Events (AEs), and Grade 3-4 Abnormalities on Laboratory Test Results During Follow-up Period</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01359644</url>
  </study>
  <study rank="101">
    <nct_id>NCT01508130</nct_id>
    <title>An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>672</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML27900</other_id>
    </other_ids>
    <first_received>January 9, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety: Time to premature treatment discontinuation due to any reason</outcome_measure>
      <outcome_measure>Efficacy: Sustained virological response rate, defined as percentage of patients with undetectable HCV RNA (HCV RNA &lt;/= 50 IU/mL) at 24 weeks post-completion of treatment</outcome_measure>
      <outcome_measure>Occurrence of premature discontinuation of treatment according to reasons (VR/resistance development/AE/compliance)</outcome_measure>
      <outcome_measure>Association between degree of dose reductions/treatment interruptions and sustained virological response</outcome_measure>
      <outcome_measure>Occurrence of virological rebound</outcome_measure>
      <outcome_measure>Virological response/virological rebound in correlation with hepatitis C virus genotype</outcome_measure>
      <outcome_measure>Virological response in relation to treatment duration after becoming HCV RNA undetectable</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH)</outcome_measure>
      <outcome_measure>Virological response in correlation with baseline clinical/demographic patient characteristics</outcome_measure>
      <outcome_measure>Virological response in correlation with treatment (regimen/dosage/compliance/co-medication)</outcome_measure>
      <outcome_measure>Treatment duration according to treatment regimens</outcome_measure>
      <outcome_measure>Percentage of patients treated according to US labeling</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Vermont</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01508130</url>
  </study>
  <study rank="102">
    <nct_id>NCT01097395</nct_id>
    <title>Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-1198</other_id>
      <other_id>K23DK082621</other_id>
    </other_ids>
    <first_received>March 30, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 6, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ribavirin AUC-12 variability</outcome_measure>
      <outcome_measure>safety - absolute hemoglobin declines</outcome_measure>
      <outcome_measure>efficacy - early and sustained virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01097395</url>
  </study>
  <study rank="103">
    <nct_id>NCT02124044</nct_id>
    <title>Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir and Dalatasvir</intervention>
      <intervention type="Drug">Daclatasvir and Asunaprevir, with or without BMS-791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institutes of Health Clinical Center (CC)</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>140065</other_id>
      <other_id>14-CC-0065</other_id>
    </other_ids>
    <first_received>April 25, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The incidence of grade 3 and 4 adverse events (AEs) followingtreatment with DCV/ASV or DCV/ASV/BMS-791325 in HIV-HCV coinfected subjects</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve SVR12</outcome_measure>
      <outcome_measure>Log change in HCV response</outcome_measure>
      <outcome_measure>The association between HIV Viral load &amp; lt; 40 copies/mL but detectable vs. undetectable while on therapy and HIV virologic failure or HIV VL blips.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02124044</url>
  </study>
  <study rank="104">
    <nct_id>NCT02247440</nct_id>
    <title>HCV-HIV Co-infected Patient Cohort in Thailand</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon + ribavirin under HIV physician supervision</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institut de Recherche pour le Developpement</lead_sponsor>
      <collaborator>Ministry of Health, Thailand</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PHPT-HCV</other_id>
    </other_ids>
    <first_received>September 9, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>April 2018</completion_date>
    <last_updated>May 24, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 6 months after treatment discontinuation</outcome_measure>
      <outcome_measure>Safety of treatment</outcome_measure>
      <outcome_measure>Impact of HCV treatment on HIV</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02247440</url>
  </study>
  <study rank="105">
    <nct_id>NCT01945008</nct_id>
    <title>Observational Study in HCV Chronic Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Istituto Superiore di Sanit</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PITER 01</other_id>
    </other_ids>
    <first_received>September 13, 2013</first_received>
    <start_date>April 2014</start_date>
    <completion_date>June 2021</completion_date>
    <last_updated>March 24, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>Liver disease progression</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) in treated patients</outcome_measure>
      <outcome_measure>Occurrence of severe adverse events and side effects correlated to treatment</outcome_measure>
      <outcome_measure>Quality of life and adherence to treatment</outcome_measure>
      <outcome_measure>Evolution of the possible comorbidities ( HIV and/or HBV coinfections)</outcome_measure>
      <outcome_measure>Occurrence of antiviral resistances</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01945008</url>
  </study>
</search_results>
